Viewing data from:

PITRESSIN TANNATE

NDA

VASOPRESSIN TANNATE | N003402 | PARKE DAVIS DIV WARNER LAMBERT CO

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

1 petition from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Lachman Consultant Services Inc. - Citizen Petition FDA-2010-P-0604 · 5 docket documents Lachman Consultant Services, Inc. filed this petition requesting that the FDA determine whether Pitressin (vasopressin tannate) Injection, 5 pressor units/mL (NDA 003402) by Parke-Davis was voluntarily withdrawn from sale for reasons of safety or effectiveness, as the product is no longer marketed a	505(q)	2010-11-24	Denied	—

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Products (1)

#001 — 5PRESSOR UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.